Molecular Partners AGMLLCF 25 3-Year ROIIC % is 1,983.27 as of Dec. 2025. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,324 Biotechnology companies, Molecular Partners AG ranks better than 96.6% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Molecular Partners AG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 1,983.27%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Molecular Partners AG's 3-Year ROIIC % or its related term are showing as below:
MLLCF's 3-Year ROIIC % is ranked better than 96.6% of 1324
companies
in the Biotechnology industry
Industry Median: -4.63
vs MLLCF: 1983.27
Molecular Partners AG (OTCPK:MLLCF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Molecular Partners AG 3-Year ROIIC % Related Terms
Molecular Partners AG 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLCF vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Molecular Partners AG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's 3-Year ROIIC % falls into.
Molecular Partners AG's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -69.565 (Dec. 2025) - 125.175 (Dec. 2022) )
/
( 8.078 (Dec. 2025) - 16.224 (Dec. 2022) )
=
-194.74
/
-8.146
=
2,390.62%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Molecular Partners AG (MLLCF) has a 3-Year ROIIC % of 1,983.27 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Molecular Partners AG and its competitors. According to the industry distribution chart, Molecular Partners AG ranks #45 out of 1324 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Molecular Partners AG's 3-Year ROIIC % too high?
Molecular Partners AG's current 3-Year ROIIC % is 1,983.27. Based on the distribution chart, Molecular Partners AG ranks #45 out of 1324 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #45 out of 1324 companies for 3-Year ROIIC %. This places Molecular Partners AG in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current 3-Year ROIIC % is 1,983.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $3.60 — trading 757.1% above its estimated fair value. The current 3-Year ROIIC % is 1,983.27. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current 3-Year ROIIC % is 1,983.27 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 757.1% above its estimated GF Value™ of $0.42.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
3-Year ROIIC %: 1,983.27
GF Value™: $0.42 vs. price of $3.60 (757.1% above fair value)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
